B6E.F Swedish Orphan Biovitrum AB (publ)

Healthcare Pharmaceuticals Frankfurt Exchange
43.80 EUR
Close of Nov 12, 2026
28.24 46.00
Market cap
EUR 15.2B
P/E
24.9x
P/B
3.71x
ROE
14.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is B6E.F undervalued?

Graham number
Price43.80
Graham value21.62
Premium102.6%

B6E.F trades 102.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Swedish Orphan Biovitrum AB (publ) fundamental analysis

No fundamental analysis for Swedish Orphan Biovitrum AB (publ) yet.

Swedish Orphan Biovitrum AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal no…

Full company profile